Navigation Links
FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
Date:4/30/2008

Advair 250/50 Now the Only Treatment Approved to Both Reduce Exacerbations

and Improve Lung Function

RESEARCH TRIANGLE PARK, N.C., April 30 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration today approved Advair Diskus(R) 250/50 (fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) who have a history of exacerbations. With this approval, Advair becomes the only treatment FDA has approved to reduce COPD exacerbations. Treatment guidelines for COPD state that the reduction of exacerbations is a key goal in managing the disease.

COPD is a progressive, life-threatening lung disease that includes chronic bronchitis, emphysema or both. Exacerbations are flare-ups or episodes of worsening COPD symptoms that often require additional treatment, such as antibiotics, oral corticosteroids and in some cases hospitalization. Symptoms may include coughing, shortness of breath, or coughing up excess mucus beyond normal day-to-day variations. Seventy-seven (77) percent of patients with COPD report experiencing at least one exacerbation within the past year.

"This is good news for my patients with COPD because Advair now brings an additional benefit in managing their disease," said Gary Ferguson, MD, Pulmonary Research Institute of Southeast Michigan. "My goal as a physician is to help reduce the number of exacerbations my patients experience and Advair 250/50 will be a critical treatment in helping meet that goal."

The FDA also expanded the use of Advair Diskus 250/50 to a broader patient population which includes not only patients with COPD associated with chronic bronchitis, but also emphysema or both conditions. Advair 250/50 is the only approved strength for COPD in the U.S., because an efficacy advantage of the higher strength over Advair 250/50 has not been demonstrated.

Advair contai
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. FDA Approves New Once-a-Month Dose of Actonel for Postmenopausal Osteoporosis
2. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
3. FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE
4. House Overwhelmingly Approves Renewal and Tripling of Successful U.S. Global AIDS Prevention Effort
5. VeriPrime Approves New Best Practices for Beef Production
6. U.S. EPA Approves Registration of Antimicrobial Copper Alloys
7. Arizona Senate Approves Smoking Cessation Treatments for State Medicaid Beneficiaries
8. CMS Approves Home Sleep Testing for Diagnosis of OSA; AASM Experts Available for Comment
9. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
10. FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting
11. FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
(Date:10/20/2014)... October 20, 2014 T.E.N., a ... firm, announced today that William H. Murray, renowned ... 2014 ISE® Luminary Leadership Award winner. Presented annually, ... of an outstanding leader and industry practitioner for ... in advancing the information security industry. , Formerly ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ... platform to think outside the bra. She doesn’t try to ... raise awareness about women’s other lady parts. , "We have ... the color pink and everybody knows what you’re talking about,” ... it has not been won when it comes to gynecologic ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 My Clients ... management software application. The new module enables easy ... receive full life-cycle quality care. , This application allows ... within their practice, attach a to-do item to a ... and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Sit and Slim II . , The FDA ... Sit and Slim II because it contains Sibutramine ... loss product on various websites and possibly in some retail ... safety reasons, can significantly increase blood pressure and/or pulse rate ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2
... A recent study by Harvard researchers suggests a link between ... people who received the vaccine were three-times more likely to ... who were not vaccinated. ,While this finding is disturbing, ... the development of MS was small -- 93 percent of ...
... caused by massive skin cancers on the face can be ... of the body. ,Most skin cancers arising on the ... family, and treatment is sought before the cancers get out ... cancers and repair the damage using flaps of skin located ...
... High levels of glycosylated hemoglobin, or HA1c, may be ... heart disease // and stroke, according to the new ... blood sugar control and the development of heart disease ... than 10,000 people, investigators found a 21-percent increase in ...
... friend might be able to detect bladder cancer . With ... malignant tumors in urine samples. ,Six dogs of ... discriminate between urine from patients with bladder cancer and that ... of urine from six control group participants and one bladder ...
... allergens and tobacco smoke could help reduce symptoms of ... than 900 children with asthma were studied. The children ... and lived in low-income areas. Previous research shows children ... at a disproportionately high rate. ,Researchers designed an ...
... even though evidence of its benefits is lacking in ... are no major benefits to surgically removing tonsils and ... examined 300 children, ages 2 to 8, with recurrent ... the children had the surgery, and half were allocated ...
Cached Medicine News:
(Date:10/20/2014)... 20, 2014  Luoxis Diagnostics, Inc., a subsidiary ... announced that its academic collaborators will present several ... for its novel RedoxSYS Diagnostic System, a first-in-class ... body in response to injury or illness.  A ... a clinical marker will be presented by ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... , Oct. 20, 2014  AnaptysBio, Inc., a ... antibodies, today announced the appointment of Marco ... Londei will lead the preclinical and clinical development ... "We are pleased to welcome Dr. Londei to ... , President and Chief Executive Officer of AnaptysBio. ...
Breaking Medicine Technology:Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... Multiplus no rub formula is the most ... All steps in one bottle without the ... your soft contact lenses and removes protein ... multi-purpose solution that contains Hydranate, a special ...
Grafton Trial Frame...
The award-winning new Universal Trial Frame (UB4), the ergonomic refraction design from Oculus that's easier to use, easier to wear....
Half Eye Trial Frame - Adult...
Medicine Products: